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376Outcomes of endovascular lower extremity
interventions depend more on indication than
physician specialty
Justin R. Wallace, MD, MSc, Theodore Yuo, MD, MSc, Luke Marone, MD, Rabih A. Chaer, MD, MSc, and
Michel S. Makaroun, MD, Pittsburgh, Pa
Objective: Outcomes of endovascular lower extremity interventions (eLEIs) have been recently linked to provider
specialty; however, the indication for intervention was not examined. We sought to compare outcomes between specialties
performing eLEI for different indications, in a recent statewide inpatient discharge dataset.
Methods: The Florida hospital discharge data from 2005 to 2009 were reviewed for patients with LEI during hospitali-
zation. We assigned provider specialty as interventional radiology (IR), interventional cardiology (IC), or vascular surgery
(VS) based on provider-associated procedures. Clinical indication was claudication or critical limb ischemia (CLI). We
limited our analysis to patients without concomitant open surgery during hospitalization. We compared mortality, length
of stay (LOS), major use of intensive care unit (ICU), discharge disposition, and total charges between specialties with
regression models, both unadjusted and adjusted for demographic and clinical characteristics.
Results: A total of 15,398 patients (47% with CLI) had an eLEI. Clinical indication was signiﬁcantly associated with
provider type (P < .001) and outcomes. VS and IR were more likely than IC to treat CLI patients (VS 59%, IR 65%, IC
26%; P < .001). IC performed the majority of procedures on claudicants (VS 30%, IC 57%, IR 13%; P < .001), while VS
performed the majority of procedures on CLI patients (VS 50%, IC 23%, IR 27%; P < .001). Adjusted analyses
demonstrated no difference in mortality rates between the three specialties (odds ratio [OR] VS: reference, IR: 1.24, IC:
0.79; P [ NS for both). However, compared with VS, IR-treated patients were less likely to be discharged home (OR,
0.74; P < .001), LOS was longer (b, 1.16 days; P < .001), major ICU use was more common (OR, 1.49; P < .001), and
total charges were higher (b, $341; P[ .001). CLI predicted poorer results for all outcomes: death (OR, 4.19; P < .001),
discharge home (OR, 0.50; P < .001), increased LOS (b, 3.26 days; P < .001), major ICU use (OR, 1.95; P < .001), and
total charges (b, $18,730; P < .001).
Conclusions: The majority of eLEI done by VS are for CLI, whereas the majority of patients treated by IC are claudicants.
Although provider specialty does correlate with several clinical results, the clinical indication for eLEI is a stronger
predictor of adverse outcomes. Future analyses of eLEI should adjust for clinical indication. (J Vasc Surg 2014;59:376-83.)Over 5 million American adults over the age of 40 have
lower extremity peripheral arterial disease (PAD), and the
prevalence more than triples in adults over 70. The preva-
lence of PAD is expected to grow substantially with the
increasing age of the U.S. population.1-4 While only
a portion of these individuals seek treatment for the disease,
primarily because of the development of symptoms, the
number of those doing so continues to grow secondary
to the less-morbid treatment paradigm of endovascular
surgery, or endovascular lower extremity interventions
(eLEIs).5 Currently, the vast majority of eLEI arethe Division of Vascular Surgery, University of Pittsburgh Medical
enter.
or conﬂict of interest: none.
ented at the Forty-ﬁrst Annual Symposium of the Society for Clinical
ascular Surgery, Miami, Fla, March 14, 2013.
itional material for this article may be found online at www.jvascsurg.org.
rint requests: Justin R. Wallace, MD, MSc, Division of Vascular Surgery,
niversity of Pittsburgh Medical Center, Ste A-1017, PUH, 200 Loth-
p St, Pittsburgh, PA 15213. (e-mail: wallacejr@upmc.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.08.004performed by vascular surgeons (VS), interventional radio-
logists (IR), and interventional cardiologists (IC). In
a recent Journal of Vascular Interventional Radiology
publication, Zafar et al proposed that the outcomes of
eLEI are linked to provider specialty, and the results of
their study demonstrated that VS have poorer outcomes
when compared with IR and IC.6 While a thorough
critique of this study has recently been published in the
Journal of Vascular Surgery,7 two major weaknesses in
the study provided the stimulus to conduct our research.
The primary limitation of the article by Zafar et al
was a failure to account for the clinical indication as a vari-
able for the measured outcomes.8,9 This clearly represents
“confounding by indication”10 and is one of the most
important limitations of observational studies leading to
a ﬂawed study design and ﬁndings. Therefore, it is impera-
tive to control for such factors in predictive models to
reduce the potential bias in treatment effect estimates.
No studies to date have evaluated the relationship among
clinical indication, clinical outcomes, and all three afore-
mentioned provider types.
The second major weakness of the Zafar et al study is
the use of a misrepresentative deﬁnition of “vascular
surgeon” that would be more appropriately termed
“surgeons,” as only one-fourth of the Centers for Medicare
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sify a provider as a vascular surgeon actually refer to
vascular surgeons. Included in their VS group are general
surgeons (02), thoracic surgeons (33), and cardiac
surgeons (78). Although eLEI may be performed by these
surgical specialties, not all have had adequate training in
eLEI, and, thus, should have been excluded from the
review.
Traditionally, patients with critical limb ischemia (CLI)
have been referred to VS for management with open revas-
cularization techniques. Open surgical revascularization of
patients with CLI has been considered the gold standard,
but endovascular interventions have recently gained wide-
spread acceptance as a viable and often effective treatment
modality for CLI patients with respectable limb salvage
rates.11,12 With the inclusion of endovascular training
during vascular surgery fellowships, there has been a signif-
icant increase in these procedures being performed by VS
representing a widespread practice shift.12,13 While some
authors have attributed this shift primarily to ﬁnancial
motivations,6 many can appreciate the patient beneﬁt in
having a vascular specialist who can offer multiple treat-
ment modalities and follow the patient longitudinally.
Thus, our study attempts to deliver a more accurate
description of short-term comparative outcomes of eLEI
as a function of provider specialty. We performed a cross-
sectional analysis of data for 5 years from a state inpatient
discharge database and compared the following ﬁve
outcomes among the three provider specialties: in-
hospital mortality, length of stay (LOS), discharge disposi-
tion, major intensive care unit (ICU) use, and total hospital
charges. This study provides the ﬁrst description of
provider-speciﬁc (VS, IR, and IC) treatment patterns for
eLEI taking into account clinical indication.
METHODS
Data source. We analyzed the Florida Agency for
Health Care Administration (AHCA) hospital inpatient
data ﬁles for 2005 to 2009 (n ¼ 12,831,451). Permission
to use the data for our study was granted by the Agency for
Health Care Administration, Florida Center for Health
Information and Policy Analysis, and the University of
Pittsburgh Institutional Review Board. This database is
part of the Agency for Healthcare Research and Quality
Healthcare Cost and Utilization Project and contains all
patient discharge records from all licensed acute care hospi-
tals, academic and private, with the exception of certain
federally funded hospitals like Veterans Affairs institu-
tions.14 The population of the state of Florida is approxi-
mately 6% of the national population, which makes it
comparable to the Medicare 5% Standard Analytical Files at
a fraction of the cost. Also, Florida’s racial diversity is
representative of the country as a whole.15 Because data are
recorded per hospitalization, we were unable to longitu-
dinally link patient records.
Data abstraction. For this study, we deﬁned eLEI as
a hospitalization that involved a lower extremity endovas-
cular intervention that involved either angioplasty orstentingdnot diagnostic angiograms alone. All patients
with a PAD severity-speciﬁc diagnosis (claudication vs
CLI) who underwent eLEI while an inpatient at a hospital
in the state of Florida during the years 2005 to 2009 were
identiﬁed by querying the Florida AHCA hospital inpatient
data ﬁle for International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) procedure codes 39.50 (angioplasty or
atherectomy of other noncoronary vessel[s]), 39.90 (inser-
tion of nondrug-eluting peripheral vessel stent[s]), and
0.55 (insertion of drug-eluting peripheral vessel stent[s]).
Patients who had an additional surgical procedure(s)
related to their vascular disease during their hospitalization
were excluded. Demographic variables analyzed included
age, sex, and race (dichotomized to white and non-white).
Comorbidities were identiﬁed using the Elixhauser tech-
nique16 and included congestive heart failure, valvular
heart disease, chronic pulmonary disease, hypertension,
diabetes, renal failure, obesity, cancer, and coagulopathy
among others. Ischemic heart disease (IHD) is not
included in the Elixhauser comorbidities, and was, thus,
determined using ICD-9 codes (410-414).
Procedure characteristics evaluated included clinical
indication (claudication vs CLI) and admission type (elec-
tive vs nonelective). Clinical indication was categorized
using ICD-9 clinically modiﬁed codes as claudication
(440.21) or CLI (rest pain [440.22], ulceration [440.23],
or gangrene [440.24]). Admission coding was used to
determine elective vs nonelective admission.
Assignment of operator type. The AHCA inpatient
data ﬁle provides the performing provider’s medical license
number and is preserved across all years of data collection.
This allowed us to identify procedures performed by
a speciﬁc provider over the study period and determine
provider specialty, as described previously.17 In short, we
selected index procedures speciﬁc to each provider specialty
(Table I), which allowed us to characterize the individual
practitioner’s specialty. We used a threshold of 90% for
discrimination purposes. For example, if the proportion of
VS vs IR vs IC codes for a given provider was greater than
90% for a particular specialty, then the provider was
assigned to that respective specialty (eg, if >90% of
procedures associated with a provider are speciﬁc to
vascular surgery, then that provider will be categorized as
a vascular surgeon). Entries associated with providers
whose ratio of index cases was not greater than 90% were
excluded. An analysis and description of provider group
volumes and procedure volume trends was performed.
Outcomes and statistical analysis. The primary
outcomes for this study were inpatient mortality, discharge
disposition (ie, home vs not home), LOS, major ICU use,
and total hospital charges. All outcomes except major ICU
use were recorded directly in the database. Use of the ICU
was discerned from the presence of ICU charges, and
“major” ICU use was deﬁned as total ICU charges that
exceeded the 95th percentile for single-day ICU use
($2680) to differentiate ICU use associated with true crit-
ical care issues vs routine postprocedure observation
utilized by many hospitals. Total hospital charges included
Table I. Index procedures with associated ICD-9 procedure codes used to identify physician specialty
VS IR IC
38.12  CEA 99.25  Chemoembolization 0.51  Implant deﬁbrillator
38.34  Ao resection with anastomosis 55.03  Percutaneous nephrostomy 0.66  PTCA
38.44  Ao resection with replacement 51.98  Percutaneous cholecystectomy 36.01  Single-vessel PTCA, no lytic
39.29  Peripheral vascular shunt
or bypass
81.65  Vertebroplasty 36.02  Single-vessel PTCA, lytic
84.15  BKA 39.1  Transjugular intrahepatic portosystemic shunt 36.05  Multivessel PTCA
84.17  AKA 99.29  Injection or infusion of other therapeutic
or prophylactic substance (UFE)
36.06  Insert non-DE coronary stent
33.26  Percutaneous lung biopsy 36.07  Insert DE coronary stent
50.11  Percutaneous liver biopsy 37.21  RHC
54.91  Percutaneous abd drainage 37.22  LHC
37.23  RHC and LHC
Abd, Abdominal; AKA, above-knee amputation; Ao, aorta; BKA, below-knee amputation; CEA, carotid endarterectomy; DE, drug-eluting; IC, interventional
cardiology; ICD-9, International Classiﬁcation of Diseases, Ninth Revision; IR, interventional radiology; LHC, left heart catheterization; PTCA, percutaneous
transluminal coronary angioplasty; RHC, right heart catheterization; UFE, uterine ﬁbroid embolization; VS, vascular surgery.
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hospital and excluded professional fees and personal conve-
nience items.
Other traditionally used outcomes of eLEI such as limb
salvage, amputation rates, wound healing, recurrence, and
reintervention rates, as well as hemodynamic outcomes
cannot be obtained from this database and were therefore
not analyzed.
After categorizing patients according to the provider
type that performed their eLEI, we compared baseline
demographic and comorbidity data using c2 analysis for
categorical variables, Student t-test for continuous, nor-
mally distributed variables, and the Kruskal Wallis test for
continuous, nonparametric variables. We described cate-
gorical data in terms of counts and proportions, normally
distributed continuous variables with means and standard
deviations, and nonparametric continuous variables with
medians and interquartile (25%-75%) ranges (IQRs).
We looked speciﬁcally at the relationship between clin-
ical indication and specialty, as well as the relationship
between clinical indication and all selected outcomes. We
also developed risk-adjusted, multivariable regression
models for each outcome of interest that allowed us to
control for dissimilar baseline characteristics. Predictor vari-
ables used included age, sex, race, elective vs nonelective
admission, IHD, and Elixhauser comorbidities. Models
were ﬁtted using backwards stepwise elimination of inde-
pendent variables with an associated P value of <2 signiﬁ-
cance level. This model ﬁtting method begins with all
independent variables in the model, then repeatedly tests
the model’s ﬁtness after stepwise removal of each indepen-
dent variable below the selection criteriondfor our
models, this criterion was a P value of <.2. Provider type
was not subjected to the selection criteria and was included
in the model regardless of its signiﬁcance level. Regression
coefﬁcients from the ﬁnal, reduced models are presented in
the Results section. Regression coefﬁcients from the full
models with all available covariates including Elixhauser
comorbidities are provided in the Appendix (online only).
Results of the logistic regression models were tabulatedas odds ratios and 95% conﬁdence intervals. Vascular
surgeons were the reference group for all regression
models. A two-tailed alpha level <.05 deﬁned statistical
signiﬁcance. Statistical analyses were performed using Stata
12.1 (StataCorp, College Station, Tex).
RESULTS
We identiﬁed 45,419 inpatients that underwent an
eLEI using ICD-9 clinically modiﬁed primary procedural
codes 39.50 (99.7%), 39.90 (0.3%), and 0.55 (0%). A
total of 27,339 patients were excluded due to lack of
a severity-speciﬁc PAD diagnosis. The most common
diagnoses among this group were “peripheral vascular
disease, unspeciﬁed,” “other complications due to renal
dialysis device, implant, and graft,” and “atherosclerosis
of renal artery.” We also excluded 2681 patients that
had undergone additional surgery, one patient with
concomitant venous ulceration as a primary diagnosis,
and 58 patients linked to providers for whom we could
not identify a specialty, which left a ﬁnal cohort for
eLEI analysis of 15,398 patients. Of the 2681 hospitaliza-
tions excluded for concomitant surgeries, 1708 (64%) had
an eLEI performed by VS, and 2236 (83%) had a diag-
nosis of CLI. Characteristics of the cohort are presented
in Table II. Overall, the majority of patients were white
(78.8%) and male (54.9%). Approximately one-half of
the study population had hypertension and IHD. The
clinical indication for 47% of eLEIs was CLI (n ¼
7197) with the remaining procedures were performed
for claudication. Among the CLI patients, 5857 (81%)
had ulcer(s) and/or gangrene, and the remainder had
rest pain only (19%).
Specialty distribution. Our algorithm assigned
a specialty to 98.5% of the observations. The total number
of individual providers for each provider group over the
duration of the study was 391 VS, 464 IR, and 486 IC.
Vascular surgeons performed 39.6% of all eLEI, slightly
less than IC (40.6%), but twice as many as IR (19.8%).
Individual VS and IC operators performed twice as many
eLEI than IR (median LEI per provider 35 for VS and
Fig 1. Physician specialty annual market share, 2005-2009.
Table II. Baseline characteristics and comorbidities for total group and physician specialty groups
Variable Total (n ¼ 15,398) VS (n ¼ 6099) IR (n ¼ 3047) IC (n ¼ 6252) P value
Age, mean (SD), years 70.7 (11.4) 71.5 (11.7) 70.2 (12.3) 70.2 (10.6) <.001
Female, % 45.1 46.8 45.1 43.4 .001
Race, %
White 78.8 78.6 69.5 83.6 <.001
Non-white 21.2 21.4 30.5 16.4 <.001
Clinical indication, %
Claudication 53.3 40.8 35.4 74.2 <.001
CLI 46.7 59.2 64.6 25.9 <.001
Comorbidities, %
Hypertension 48.9 53.8 45.0 45.9 <.001
Diabetes 29.6 34.2 30.5 24.7 <.001
Renal failure 15.5 16.8 20.9 11.7 <.001
IHD 50.7 41.4 42.5 63.9 <.001
Valvular heart disease 4.3 3.5 4.6 4.8 .001
Congestive heart failure 9.8 10.3 11.2 8.8 .001
Chronic lung disease 14.5 15.8 14.7 13.1 <.001
Obesity 4.1 4.6 4.9 3.3 <.001
Admission type, %
Nonelective 44.9 43.6 57.9 39.9 <.001
Elective 55.1 56.4 42.1 60.1 <.001
Number of comorbidities, %
0 18.9 17.7 26.5 16.4 <.001
1 22.1 17.1 19.4 28.2 <.001
2 8.6 10.7 6.6 7.7 <.001
$3 50.4 54.5 47.5 47.8 <.001
Insurance type, %
Medicare 77.5 79.5 76.8 75.9 <.001
Medicaid 3.6 3.6 5.5 2.9 <.001
Commercial 15.1 13.5 12.8 17.7 <.001
Self-pay 1.3 1.4 2.0 0.8 <.001
Other 2.5 2.0 2.9 2.7 .01
CLI, Critical limb ischemia; IC, interventional cardiology; IHD, ischemic heart disease; IR, interventional radiology; SD, standard deviation; VS, vascular
surgery.
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groups per year is provided in Fig 1 and demonstrates an
annual increase in total proportion of eLEI performed by
VS from 28% in 2005 to 48% in 2009. An annual decline
for IR and IC is apparent with the IR eLEI proportion
decreasing from 25% to 20% and IC from 47% to 33%.
Provider group populations. Analysis of baseline
patient characteristics and comorbidities revealed signiﬁ-
cant differences in patient populations among the three
provider types (Table II). The VS and IR patient pop-
ulations were generally similar. However, the IC patient
population was more likely to be white, and less likely to
have comorbidities, except for IHD and valvular heart
disease. They were also more likely to carry the diagnosis of
claudication opposed to CLI. VS treated more patients
with hypertension, diabetes and chronic lung disease. IR
treated more patients with renal failure, CHF, and obesity.
Patients treated by IR were more likely to have been
admitted nonelectively (57.9%), whereas the majority or
VS and IC patients were admitted electively (56.4% and
60.1%, respectively). Compared with the other specialties,
VS treated one-half of all CLI patients (n ¼ 3611; 50%;
P < .001), while IC treated the most claudicants (n ¼
4633; 57%; P < .001; Fig 2).
Confounding analysis. The association of clinical
indication with provider type was statistically signiﬁcant(P < .001). Univariate analysis found CLI to indepen-
dently and signiﬁcantly inﬂuence poorer results for all
outcomes. CLI patients were fundamentally different
than claudicants. Because vascular surgeons treat more
patients with CLI, clinical indication was determined to
be a confounding factor and further justiﬁed its inclusion
in our multivariable regression models.
As previously described, VS and IR treated predomi-
nantly CLI patients, and IC treated mostly claudicants.
Thus, it was no surprise that results of outcome analyses
for each provider specialty compared to the other
Fig 2. Physician specialty breakdown for clinical indication. CLI, Critical limb ischemia; IC, interventional cardiology;
IR, interventional radiology.
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indication (Table III). All indication-adjusted outcome
results for VS and IR improved, however, the improve-
ments were most optimal for VS. Conversely, adjustment
for clinical indication worsened all IC outcome results.
Univariate analysis of outcomes. The overall inpa-
tient mortality rate was 1.3%. Mortality was highest for
IR (2.2% vs 1.5% VS vs 0.7 IC; P < .001). Seventy percent
of patients were discharged home at the conclusion of their
inpatient hospitalization. VS and IC patients were dis-
charged home 73% of the time, while IR patients were dis-
charged home only 60% of the time (P < .001). The
median LOS for patients undergoing inpatient eLEI was
2 days (IQR, 1-6 days). Median LOS varied signiﬁcantly
among the provider types with IR patients staying the
longest (5 days; IQR, 1-9 days). VS patients stayed
a median of 2 days (IQR, 1-6 days), and IC patients had
the shortest median LOS (1 day; IQR, 1-2 days). Approx-
imately one-fourth (24.3%) of all patients required major
ICU use. Major ICU utilization varied signiﬁcantly with
25% use by VS compared with 19% by IC and 35% by IR
(P < .001). Lastly, the median total hospital charges for all
patients was $46,900 (IQR, $31,600-$72,400) and
differed signiﬁcantly among specialties with IR ($54,800)
> VS ($49,800) > IC ($41,400).
Multivariable analysis of outcomes (see Appendix
for full models including Elixhauser comorbidities).
Reduced model outputs for the multivariable regressions
are displayed in Table IV. Outcome analysis adjusted for
all predictor variables found the presence of CLI to be
signiﬁcantly associated with worse results for all outcomes
except major ICU use for which clinical indication made
no signiﬁcant difference. Specialty was not predictive of
inpatient mortality, but compared to VS, treatment by IR
was signiﬁcantly associated with a decreased chance of
being discharged home, a longer LOS, and increased major
ICU use. Compared to VS, IC-treated patients were more
likely to be discharged home, have a shorter LOS, and
decreased total hospital charges.DISCUSSION
The primary aim of this study was to clarify the true
predictors of various outcomes of eLEI. We believe the
most signiﬁcant ﬁnding of this study was that clinical indi-
cation, not provider specialty, is most predictive of many
outcomes following eLEI. In practice, the association
between clinical indication for the procedure and outcome
is intuitive, as most would agree that patients with more
advanced disease will have worse outcomes. Also, clinical
indication has been shown to be a signiﬁcant prognostic
factor for outcomes in infrainguinal endovascular proce-
dures.8,9,18 Scali et al demonstrated that among patients
who underwent SFA endovascular revascularization proce-
dures, those with CLI had poorer patency and amputation-
free survival rates than patients with claudication.8 In
a study published in 2005, Trocciola et al examined their
patency and limb salvage outcomes for endovascular treat-
ment of infrainguinal arterial disease in claudicants vs
patients with CLI.9 Although the comparative results
were not signiﬁcantly different, a trend toward improved
patency and limb salvage was demonstrated. Lastly, and
similar to our ﬁndings, Sachs et al showed that CLI patients
experience higher in-hospital mortality following eLEI
compared with claudicants (2.1% vs 0.2%).18 However,
despite this body of evidence, Zafar et al chose not to
include clinical indication in their predictive models.
In our efforts to provide a more accurate description of
the short-term comparative outcomes of eLEI as a function
of provider specialty, we believe this retrospective, cross-
sectional study of the Florida inpatient hospital discharge
database from 2005 to 2009 reveals several important
and interesting ﬁndings. On a matter of external validity,
the rate of diabetes in this study is lower than may have
been expected,19-21 especially in the VS and IR cohorts
that were mostly CLI patients. However, this may in fact,
be the rate in the general population as opposed to more
properly controlled series of CLI. This analysis showed
that VS, IR, and IC treat different patient populations.
Table III. Confounding effect of clinical indication on physician specialty outcomes
VS
VS vs non-VS VS vs non-VS (with clinical indication) % change
OR 95% CI OR 95% CI
Inpatient death 1.26 0.95-1.67 0.91 0.68-1.20 28
Major ICU use 1.04 0.97-1.12 0.83 0.76-0.90 20
Discharge home 1.20 1.11-1.28 1.45 1.34-1.56 21
beta 95% CI beta 95% CI
LOS, days .54 0.33-0.74 .56 0.75-0.36 204
Total charges, $ 4760 3140-6380 1370 2960-210 129
IR
IR vs non-IR IR vs non-IR (with clinical indication) % change
OR 95% CI OR 95% CI
Inpatient death 2.08 1.55-2.80 1.51 1.12-2.03 27
Major ICU use 1.89 1.74-2.06 1.56 1.43-1.70 17
Discharge home 0.55 0.51-0.60 0.64 0.59-0.70 16
beta 95% CI beta 95% CI
LOS, days 3.02 2.78-3.27 1.92 1.70-2.16 36
Total charges, $ 12,500 10,500-14,500 6160 4220-8090 51
IC
IC vs non-IC IC vs non-IC (with clinical indication) % change
OR 95% CI OR 95% CI
Inpatient death 0.39 0.28-0.55 0.71 0.50-1.01 82
Major ICU use 0.60 0.55-0.65 0.85 0.78-0.92 42
Discharge home 1.27 1.18-1.36 0.95 0.88-1.03 25
beta 95% CI beta 95% CI
LOS, days 2.52 2.73-2.32 .80 0.99-0.60 68
Total charges, $ 13,000 14,600-11,400 2980 4620-1330 77
CI, Conﬁdence interval; IC, interventional cardiology; ICU, intensive care unit; IR, interventional radiology; LOS, length of stay; OR, odds ratio; VS, vascular
surgery.
Regression outputs before and after adjustment for clinical indication.
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thirds were claudicants. In comparison, almost two-thirds
of VS and IR patients had CLI. Vascular surgeons treated
as many CLI patients as IC and IR specialists combined.
Interestingly, additional analysis did demonstrate an annual
pan-specialty shift in eLEI indication with fewer claudicants
being treated as inpatients.
Specialty variations in clinical indications for endovas-
cular treatments have been explored for both carotid and
peripheral endovascular interventions.17,22 Although no
signiﬁcant difference in clinical indication was found
among VS, IR, and IC for carotid artery stenting proce-
dures,17 a comparison of patients treated by VS and IC
for lower extremity angioplasty by Vogel et al found that
VS are signiﬁcantly more likely to treat patients with CLI
than claudication while just the opposite was identiﬁed
for IC.22 Notably, IR was not included in this comparative
analysis. Their study also effectively demonstrated the
profound inverse effect that physician endovascular proce-
dure volume has on resource utilization. The signiﬁcant
relationship between higher procedure volume and
improved outcomesdboth on a hospital level anda provider leveldhas been well documented in the endo-
vascular era.23,24 Although we did not include volume
data in our prediction models, worse outcomes were
observed in the lower-volume specialty.
Our eLEI specialty distribution analysis corroborated
that of other investigators and demonstrated a declining
percentage of eLEI performed by IRda percentage that
was overcome by VS and IC in 2003.5 The IR proportion
of eLEI was already below VS and IC at the initial year of
our study (2005), but it continued to decline until 2008
when the rate of decline leveled. The Florida inpatient VS
distribution appears to have been greater than that of IC
in 2008 and continued to rise into 2009 to almost one-
half of all eLEI. The proportion of eLEI performed by IC
was greatest in 2005 at 47% but has since declined to 33%.
Because the presence of CLI inﬂuenced the treating
specialty as well as the results of most analyzed outcomes
of this study, we can deﬁnitively state that clinical indica-
tion is a confounder. Therefore, confounding by indication
is indeed present, and any conclusions drawn regarding
outcomes by provider type without including the clinical
indication would be wrong or inaccurate at best. The ideal
Table IV. Reduced multivariable regression model
outputs for all outcomes
Outcome
Predictor
variable OR 95% CI P value
Inpatient mortality
VS Reference
IR 1.24 0.90-1.73 .19
IC 0.79 0.53-1.16 .22
CLI 4.19 2.68-6.56 <.001
Discharge
disposition,
home
VS Reference
IR 0.74 0.66-0.82 <.001
IC 0.87 0.79-0.96 .005
CLI 0.50 0.46-0.55 <.001
Major ICU use
VS Reference
IR 1.49 1.35-1.64 <.001
IC 0.99 0.90-1.08 .78
CLI 1.95 1.79-2.14 <.001
Outcome
Predictor
variable Betaa 95% CI
P
value
LOS,
additional
days
VS Reference
IR 1.16 0.93-1.4 <.001
IC 0.42 0.62-0.22 <.001
CLI 3.26 3.07-3.46 <.001
Total hospital
charges,
additional $
VS Reference
IR 3410 1390-5430 .001
IC 1630 3330-70 .06
CLI 18,730 17,060-20,400 <.001
CI, Conﬁdence interval; CLI, critical limb ischemia; IC, interventional
cardiology; ICU, intensive care unit; IR, interventional radiology; LOS,
length of stay; OR, odds ratio; VS, vascular surgery.
aBeta represents the regression coefﬁcient for linear regression models.
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pendent variable is through randomization in a clinical trial.
However, with retrospective review analyses, several
options exist to reduce the confounder’s inﬂuence and
maximize a study’s external validity.25 Due to the
complexity of propensity score analysis with three treat-
ment/provider groups, we chose to use multivariable
regression to control for the confounding of clinical indica-
tion. Even without adjustment for clinical indication, IR
outcomes were less favorable than VS and IC, which
contrasts with the ﬁndings of Zafar et al. The reason for
this is not entirely clear, but it likely stems from the
different methods and databases used. Replication of the
Journal of Vascular Interventional Radiology study with
adjustment for clinical indicationdand a more speciﬁc VS
deﬁnitiondcould offer more conclusive detail.
Finally, outcomes by provider group did differ signiﬁ-
cantly for most outcomes. In fact, IR-treated patients,compared with VS-treated patients, were 27% less likely to
be discharged home, stayed one more day in the hospital,
were 49% more likely to require major ICU use, and charged
over $4000 more per inpatient hospital stay. Our ﬁndings
contradict the economic and disposition ﬁndings publicized
in some studies uncontrolled for clinical indication,6 and in
fact, suggest decreased resource utilization, and more likely
discharge to home for patients treated by non-IR specialties.
Although a detailed cost analysis was not plausible with the
AHCA database, it is interesting to consider the ﬁndings of
one recent study that found signiﬁcant hospital cost reduc-
tions when eLEIs were performed in a radiology suite com-
pared with the operating room.26 As VS are the principal
providers to perform eLEI in the operating room, a VS
procedural setting transition could broaden the signiﬁcant
provider cost difference detected in this study.
Limitations. Because our study is a retrospective anal-
ysis and not a randomized controlled trial, it is subject to
confounding. However, in an attempt to adjust for known
confounders, we performed multivariable logistic and linear
regression in our analysis. We recognize that unmeasured
confounders are still possible, as they are in all observa-
tional studies of administrative data. One such confound-
ing variable that we were unable to control for is the
referral pattern inherent to different hospitals speciﬁc to
the three specialties analyzed. Referral patterns may have
inﬂuenced such outcomes as LOS for IR, as they may get
many referrals from in-hospital physicians.
In this particular database, the hospitalizations are the
unit of analysis, not the patients. Thus, the inability to
link patients longitudinally prevents our ability to deter-
mine reintervention or limb salvage rates. We also acknowl-
edge the general, inherent limitations of administrative
databases that have been described, clerical errors and
under-reporting of procedures with minimal ﬁnancial
incentive,27,28 but high-revenue procedures, such as eLEIs,
are typically well captured and afford valid studies.29
Another issue with using this administrative database is
the fact that we excluded many patients who had additional
surgical procedures. This represented 15% of the total, and
83% of them had CLI. We believe there were many imper-
atives to exclude these patients that included the inability
to determine who performed the additional procedures.
Additionally, one specialty (VS) was disproportionately
involved in two-thirds of these patients, and it would
have otherwise skewed the results of this specialty.
Limitations of an analysis based on ICD-9 procedure
codes include the inability to reliably quantify and differen-
tiate all eLEIs performed during each procedure, the lack
of anatomic detail, and the inability to determine tempo-
rality of adverse events and ICU stay with respect to the
procedure itself.
Lastly, with the majority of eLEIs performed on an
outpatient basis, at ﬁrst glance, the inpatient-only sample
represents one of this study’s major limitations. However,
this inpatient cohort provides a more homogenous group
of patients that allowed us to concentrate those eLEIs per-
formed on higher-risk patients as well as those eLEIs with
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 2 Wallace et al 383less favorable outcomes. This more similar patient cohort
improves our ability to detect an actual outcome difference
among the provider groups.
CONCLUSIONS
CLI is a stronger predictor than provider specialty for
adverse outcomes following eLEIs. Speciﬁcally, CLI in
hospitalized patients that undergo eLEI is associated with
signiﬁcantly increased odds of dying, being in the ICU,
having a longer LOS, incurring higher total hospital
charges, and not being discharged home. Vascular
surgeons treat one-half of all CLI patients, and interven-
tional cardiologists treat mostly claudicants. Thus, analysis
of outcomes by provider without adjusting for clinical indi-
cation provides biased and invalid results. When outcome
models adjust for clinical indication, IR-treated patients,
in fact, do worse than VS-treated patients except for inpa-
tient mortality for which there is no specialty difference.
Future outcome analyses of eLEIs should adjust for clinical
indication.
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Appendix (online only). Full multivariable regression models for all outcomes (includes Elixhauser comorbidities)
Inpatient mortality
Logistic regression Number of obs ¼ 15398
LR c2(14) ¼ 317.82
Prob > c2 ¼ 0.0000
Log likelihood ¼ 904.18887 Pseudo R2 ¼ 0.1495
Death Odds ratio Std. Err. z P>jzj 95% conﬁdence interval
provider
IR 1.244812 .209535 1.30 0.193 .8950014 1.731345
IC .786338 .1547032 1.22 0.222 .5347427 1.156308
age 1.026289 .0067526 3.94 0.000 1.013139 1.03961
CLI 4.194806 .9577143 6.28 0.000 2.681479 6.562198
sex 1.385078 .2062355 2.19 0.029 1.034504 1.854456
nonwhite .8254562 .1464925 1.08 0.280 .5829517 1.168841
electadmit .4083418 .0718088 5.09 0.000 .2892918 .5763836
CHF 2.257157 .4174149 4.40 0.000 1.570903 3.243202
met cancer 9.70768 4.844143 4.55 0.000 3.650606 25.81463
liver disease 6.336147 2.776288 4.21 0.000 2.684461 14.95524
COPD 1.266722 .2459187 1.22 0.223 .8658262 1.85324
HTN, uncomp .2429104 .0574979 5.98 0.000 .1527436 .386304
paralysis 10.78228 8.783013 2.92 0.004 2.184441 53.22075
hypothyroid 1.513414 .3430352 1.83 0.068 .9705589 2.359901
_cons .0009445 .0005096 12.91 0.000 .0003281 .0027191
Discharge disposition (home vs not home)
Logistic regression Number of obs ¼ 15398
LR c2(19) ¼ 3360.94
Prob > c2 ¼ 0.0000
Log likelihood ¼ 7677.3402 Pseudo R2 ¼ 0.1796
dc home Odds ratio Std. Err. z P>jzj [95% Conf. Interval]
Provider
IR .7350571 .0388638 5.82 0.000 .6626994 .8153153
IC .8733454 .0419698 2.82 0.005 .7948412 .9596032
age .9736651 .0017557 14.80 0.000 .9702301 .9771122
CLI .5024644 .0228908 15.11 0.000 .4595439 .5493936
sex .9553955 .0385618 1.13 0.258 .882728 1.034045
psychoses .1805314 .0706524 4.37 0.000 .0838355 .3887563
electadmit 1.332583 .0555521 6.89 0.000 1.228032 1.446035
CHF .6336714 .0504714 5.73 0.000 .5420841 .7407328
valve disease .8673009 .0987343 1.25 0.211 .6938542 1.084105
F&E disorder .5300596 .0488174 6.89 0.000 .4425178 .6349195
PVD 5.099817 .2905977 28.59 0.000 4.56091 5.702401
HTN, uncomp 2.161537 .1449684 11.49 0.000 1.895286 2.46519
paralysis .1771282 .1104597 2.78 0.006 .0521755 .6013248
oth neuro dis .2683648 .0603051 5.85 0.000 .1727625 .4168712
weight loss .3139558 .0629831 5.77 0.000 .2118888 .4651886
hypothyroid .7294408 .0672591 3.42 0.001 .6088409 .8739294
tumor no mets .628006 .1443913 2.02 0.043 .40018 .9855355
liver disease .4412315 .1197846 3.01 0.003 .2591696 .7511886
2.90 0.004 1.071713 1.429061
16.89 0.000 7.685636 13.12654
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HTN, comp 1.237556 .0908482
Length of stay
Source SS df MS Number of obs ¼ 15398
Model 177,515.809 23 7718.07867 F(23, 15374) ¼ 266.53
Residual 445,200.393 15,374 28.9580065 Prob > F ¼ 0.0000
Total 622,716.202 15,397 40.4439957 R-squared ¼ 0.2851
Adj R-squared ¼ 0.2840
Root MSE ¼ 5.3813
los days Coef. Std. Err. t P>jtj [95% Conf. Interval]
Provider
IR 1.164363 .1217384 9.56 0.000 .9257411 1.402985
IC .4221568 .1023468 4.12 0.000 .6227687 .2215449
age .023463 .0039259 5.98 0.000 .0311583 .0157677
CLI 3.264988 .1004731 32.50 0.000 3.068049 3.461927
sex .4230499 .0891596 4.74 0.000 .2482865 .5978134
nonwhite .9602731 .1107002 8.67 0.000 .7432876 1.177259
electadmit 2.275735 .0923298 24.65 0.000 2.456713 2.094758
CHF 1.723701 .1779463 9.69 0.000 1.374905 2.072497
valve disease .9791889 .2413675 4.06 0.000 .5060801 1.452298
pulm HTN 1.136249 .4162948 2.73 0.006 .3202617 1.952236
PVD 1.04183 .0968073 10.76 0.000 1.231584 .8520763
F&E disorder 2.15699 .2116971 10.19 0.000 1.742039 2.571942
paralysis 5.025083 1.496333 3.36 0.001 2.092093 7.958073
depression 1.462656 .2855523 5.12 0.000 .9029394 2.022372
COPD .4071396 .1386665 2.94 0.003 .1353368 .6789423
hypothyroid .7015748 .192752 3.64 0.000 .323758 1.079392
renal failure 1.919619 .1378302 13.93 0.000 1.649456 2.189783
liver disease 4.267675 1.207022 3.54 0.000 1.901769 6.63358
AIDS/HIV 11.32554 1.151751 9.83 0.000 9.067968 13.58311
psychoses 2.448946 .9123256 2.68 0.007 .6606798 4.237212
weight loss 6.266815 .488911 12.82 0.000 5.308492 7.225139
tumor no mets 1.34782 .5118351 2.63 0.008 .3445627 2.351078
RA/CV disease .7781035 .4219584 1.84 0.065 .048985 1.605192
_cons 4.996222 .2995634 16.68 0.000 4.409042 5.583401
Major ICU use
Logistic regression Number of obs ¼ 15398
LR c2(17) ¼ 1620.12
Prob > c2 ¼ 0.0000
Log likelihood ¼ 7738.8724 Pseudo R2 ¼ 0.0948
Major icu Odds ratio Std. Err. z P>jzj [95% Conf. Interval]
Provider
IR 1.489721 .0773609 7.68 0.000 1.345557 1.64933
IC .9862778 .0477979 0.29 0.776 .8969072 1.084554
CLI 1.953566 .0890725 14.69 0.000 1.78656 2.136183
liver disease 1.781799 .4332349 2.38 0.018 1.106353 2.869616
sex 1.049449 .0425376 1.19 0.234 .9693025 1.136222
nonwhite 1.267293 .0598315 5.02 0.000 1.155287 1.390157
electadmit .5480646 .0228537 14.42 0.000 .5050537 .5947383
CHF 1.587361 .1115029 6.58 0.000 1.383196 1.821661
valve disease 1.361748 .1315951 3.20 0.001 1.126781 1.645714
lymphoma 2.0195 1.073976 1.32 0.186 .7121516 5.726843
PVD 1.270413 .0570023 5.33 0.000 1.163462 1.387195
F&E disorder 1.611847 .1321348 5.82 0.000 1.372602 1.892792
psychoses 1.717908 .6057767 1.53 0.125 .8606869 3.428898
coagulopathy 4.487249 2.401512 2.81 0.005 1.571915 12.80947
COPD 1.376046 .0798073 5.50 0.000 1.228189 1.541703
hypothyroid 1.25019 .0996853 2.80 0.005 1.069312 1.461664
renal failure 1.379119 .0768302 5.77 0.000 1.236464 1.538232
_cons .1829812 .011089 28.03 0.000 .1624883 .2060586
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Total hospital charges
Source SS df MS Number of obs ¼ 15398
Model 6.8426eþ12 22 3.1103eþ11 F(22, 15375) ¼ 149.49
Residual 3.1988eþ13 15,375 2.0805eþ09 Prob > F ¼ 0.0000
Total 3.8831eþ13 15,397 2.5220eþ09 R-squared ¼ 0.1762
Adj R-squared ¼ 0.1750
Root MSE ¼ 45613
Total chgs Coef. Std. Err. t P>jtj [95% Conf. Interval]
Provider
IR 3410.101 1031.783 3.31 0.001 1387.684 5432.518
IC 1630.233 867.5456 1.88 0.060 3330.726 70.25861
age 248.265 33.24911 7.47 0.000 313.4372 183.0928
CLI 18,728.43 851.9691 21.98 0.000 17,058.47 20,398.4
sex 1124.768 755.1689 1.49 0.136 355.4529 2604.988
nonwhite 5361.61 939.3368 5.71 0.000 3520.399 7202.821
electadmit 10466.24 782.5231 13.37 0.000 12000.08 8932.403
CHF 12,160.71 1508.174 8.06 0.000 9204.508 15,116.91
valve disease 8697.538 2045.184 4.25 0.000 4688.736 12,706.34
pulm HTN 12,278.95 3528.974 3.48 0.001 5361.747 19,196.16
PVD 764.813 1046.02 0.73 0.465 1285.51 2815.136
HTN, uncomp 5073.405 1100.999 4.61 0.000 2915.317 7231.493
paralysis 45,468.49 12,683.08 3.58 0.000 20,608.15 70,328.83
weight loss 40,748.45 4143.834 9.83 0.000 32,626.04 48,870.85
COPD 6158.236 1176.929 5.23 0.000 3851.317 8465.155
hypothyroid 4421.722 1635.27 2.70 0.007 1216.398 7627.045
renal failure 17,506.6 1347.378 12.99 0.000 14,865.58 20,147.62
liver disease 40,963.74 5242.942 7.81 0.000 30,686.96 51,240.53
psychoses 11,394.11 7734.496 1.47 0.141 3766.419 26,554.63
F&E disorder 16,403.94 1795.087 9.14 0.000 12,885.35 19,922.52
metastatic CA 42,857.6 7075.27 6.06 0.000 28,989.24 56,725.97
RA/CV disease 6916.357 3575.894 1.93 0.053 92.81907 13,925.53
_cons 63,945.97 2537.318 25.20 0.000 58,972.52 68,919.41
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